Summary
Fabry disease is an inherited lysosomal storage disease caused by deficiency of α-galactosidase A. Enzyme replacement therapy for this multisystem progressive disease has been available only since 2001. We here report the first known successful pregnancy of a female patient receiving such therapy.
Article PDF
Avoid common mistakes on your manuscript.
References
Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M (2003) Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 26: 617–627.
Elstein Y, Eisenberg V, Granovsky-Grisaru S, et al (2004) Pregnancies in Gaucher disease: a 5-year study. Am J Obstet Gynecol 190: 435–441.
MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38: 769–775.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wendt, S., Whybra, C., Kampmann, C. et al. Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. J Inherit Metab Dis 28, 787–788 (2005). https://doi.org/10.1007/s10545-005-0018-9
Issue Date:
DOI: https://doi.org/10.1007/s10545-005-0018-9